The RealReal to Participate in Fireside Chat Hosted by Wells Fargo
SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) — The RealReal (Nasdaq: REAL)—the world’s largest online marketplace for authenticated, resale luxury goods—today […]
UPDATE – Leading PACE Provider InnovAge Selected to Participate in National Study Focused on Preventing Falls by Seniors
DENVER, Sept. 16, 2024 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by InnovAge Holding […]
Zoom for Government Platform Expands With Zoom AI Companion, Receives FedRAMP® JAB Authorization
SAN JOSE, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) — Today, Zoom announced that The Federal Risk and Authorization Management Program […]
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
ISELIN, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval […]
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
Of the 20 evaluable ovarian cancer patients, there were 5 PRs Of the 43 evaluable ICI-naïve MSS/MSI-L CRC patients without […]
FactSet Announces Investor Day 2024
NORWALK, Conn., Sept. 16, 2024 (GLOBE NEWSWIRE) — FactSet (NYSE: FDS | NASDAQ: FDS), a global financial digital platform and enterprise […]
InterDigital Announces Annual Recurring Revenue Target Of $1 Billion By 2030
WILMINGTON, Del., Sept. 16, 2024 (GLOBE NEWSWIRE) — InterDigital, Inc. (Nasdaq: IDCC), a mobile, video and AI technology research and […]
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology […]
Haleon Selects PubMatic as Supply Optimisation Partner to Enable More Effective, Sustainable Media Buying
LONDON, Sept. 16, 2024 (GLOBE NEWSWIRE) — PubMatic (NASDAQ:PUBM), an independent technology company delivering digital advertising’s supply chain of the […]
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
– Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases […]
